References
Shah M, Coates M. An assessment of the quality of life in older patients with skin disease. Br J Dermatol 2006; 154: 150–3.
Essers BAB, Nieman FHM, Prins MH, et al. Determinants of satisfaction with the health state of the facial skin in patients undergoing surgery for facial basal cell carcinoma. Patient Educ Couns 2006;60:179–86.
Rhee JS, Matthews BA, Neuburg M, et al. Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer. Arch Facial Plast Surg 2006; 8: 314–8.
Strittmatter G, Mawick R, Tilkorn M. Hornheider Fragebogen. In: Pychodiagnostische Verfahren für die Dermatologie. Kupfer J, Schmidt S Augustin M. Hogrefe: Göttingen, 2006: 123–8.
Strittmatter G, Tilkorn M, Mawick R. How to identify patients in need of psychological intervention. Recent Results Cancer Res 2002;160:353–61.
Gaitanis G, Alexopoulos EC, Bassukas ID. Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study. Eur J Dermatol 2011;21:952–8.
Gaitanis G, Bassukas ID. Immunocryosurgery for non-superficial basal cell carcinomas =20 mm in maximal diameter: five-year follow-up. J Geriatr Oncol 2018: 30069–79, pii: S1879-4068(18).
Rhee JS, Matthews BA, Neuburg M, et al. Skin cancer and quality of life: assesment with the Dermatology Life Quality Index. Dermatol Surg 2004;30:525–9.
Chen T, Bertenthal D, Sahay A, et al. Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch Dermatol 2007; 143: 1386–92.
Harrison JD, Young JM, Price MA, et al. What are the unmet supportive care needs of people with cancer? A systematic review. Support Care Cancer 2009; 17:1117–28.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Bassukas, I.D., Ganiatsa, A. & Gaitanis, G. Health-related quality of life associated with immunocryosurgery, a minimally invasive modality, for cervicofacial basal cell carcinoma. Eur J Dermatol 29, 234–236 (2019). https://doi.org/10.1684/ejd.2019.3521
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2019.3521